CSPC Innovation Pharmaceutical (SZSE:300765) Sheds 3.6% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Huafu Securities: Significant differentiation in pharmaceutical interim reports, bullish on Pharma and innovative drugs.
Fundamentally, last week saw a high concentration of pharmaceutical mid-year reports, with some differentiation but overall industry pressure and bearish expectations materializing. Considering the upward year-on-year growth rate in the industry in Q3, along with the upcoming catalytic factors such as the implementation of innovative drug industry chain support policies and the start of medical insurance negotiations, the overall trend of the industry is upward.
CSPC Innovation Pharmaceutical's (SZSE:300765) Sluggish Earnings Might Be Just The Beginning Of Its Problems
CSPC Innovation Pharmaceutical: Half-year report for the year 2024.
CSPC Innovation Pharmaceutical: Summary of Half-Year Report in 2024.
Due to lower caffeine prices, CSPC Innovation Pharmaceutical's Q2 performance continued the downward trend from Q1. | Interpretations
Due to factors such as the decline in caffeine prices, CSPC Innovation Pharmaceutical's revenue and net income have both declined. Several pipelines in CSPC Innovation Pharmaceutical have made progress, and Enracuab monoclonal antibody has been conditionally approved for listing in June of this year. In order to enhance the industrialization capability of monoclonal antibody and ADCs, the company announced that CSPC Biotech will invest in the construction of two production line projects.
CSPC Innovation Pharmaceutical (300765.SZ): Jusheng Biotech plans to build a monoclonal antibody production line and ADC new product commercial production line, with a total investment of no more than 0.9 billion yuan.
CSPC Innovation Pharmaceutical (stock code 300765.SZ) announced that its subsidiary CSPC Pharma's Jusheng Bio-Pharmaceutical Co., Ltd. (referred to as ...
CSPC Innovation Pharmaceutical (300765.SZ): Net income in the first half of the year was 0.137 billion yuan, a YoY decrease of 48.27%.
CSPC Innovation Pharmaceutical (300765.SZ) released its 2024 interim report, with a reported revenue of 0.972 billion yuan, a year-on-year decrease of 27.71%; net income attributable to shareholders of the listed company was 0.137 billion yuan, a year-on-year decrease of 48.27%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.134 billion yuan, a year-on-year decrease of 65.87%; basic earnings per share was 0.10 yuan.
CSPC Innovation Pharmaceutical (300765.SZ): Has accumulated repurchased 0.85% of its shares.
CSPC Innovation Pharmaceutical (300765.SZ) announced that it has repurchased 11,958,125 shares of the company through a share repurchase special securities account using centralized bidding trading method as of July 31, 2024, accounting for 0.85% of the company's current total share capital, with a maximum fill price of 34.99 yuan/share, a minimum fill price of 18.68 yuan/share, and a total amount paid of 31.997 billion yuan (excluding transaction fees).
CSPC Innovation Pharmaceutical (300765.SZ): As of July 19, 2024, the company's total number of shareholders, including ordinary accounts and finance and securities lending credit accounts, was 16,352.
On July 22nd, Geely News reported that as of July 19, 2024, the number of shareholders of CSPC Innovation Pharmaceutical, which merged regular accounts and finance and securities lending credit accounts, reached 16,352 on the investor interaction platform.
A Look At The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)
CSPC Innovation Pharmaceutical (300765.SZ): SYS6016, a respiratory syncytial virus mRNA vaccine, has been approved for clinical trials.
CSPC Innovation Pharmaceutical, a subsidiary of CSPC Pharma (300765.SZ), has announced that its subsidiary, Aino BioPharma Co., Ltd. ("Aino BioPharma"), has entered into a share purchase agreement with Allarity Therapeutics A/S.
CSPC Innovation Pharmaceutical (300765.SZ): The clinical trial application of SYS6023 injection from Jushi Bio has been approved by the FDA in USA.
On July 8th, GeLongHui reported that CSPC Innovation Pharmaceutical's holding subsidiary, CSPC Pharma, had received notification from the US Food and Drug Administration (FDA) that their clinical trial application for injection drug SYS6023 had been approved for clinical trials in the US. SYS6023 is a monoclonal antibody drug conjugate that can bind to a specific receptor on the surface of the tumor, enter the cell through internalization, release toxins, and achieve the effect of killing tumor cells. This product.
cspc innovation pharmaceutical (300765.SZ): Cumulative expenditure of 227 million yuan to repurchase 8.0808 million shares.
On July 1st, Gelunhui reported that CSPC Innovation Pharmaceutical (300765.SZ) repurchased 8,080,805 shares of the company's stock through a share repurchase dedicated securities account by concentrated bidding trading method, accounting for 0.58% of the company's current total share capital as of June 30, 2024. The highest fill price was 34.99 yuan/share, the lowest fill price was 18.68 yuan/share, and the total amount paid was 227 million yuan (excluding transaction fees).
CSPC Innovation Pharmaceutical (300765.SZ): Enrepta single monoclonal antibody injection of Giant Stone Biology has received conditional approval for drug listing application.
CSPC Innovation Pharmaceutical (300765.SZ) announced on June 28 that its controlling subsidiary, CSPC Pharma (Jiushi Bio) Co., Ltd. (referred to as "Jiushi Bio"), recently obtained conditional approval from the National Medical Products Administration for the listing application of Enlangsubai monoclonal antibody injection (trade name: Ensuximab). Ensuximab is a recombinant anti-PD-1 fully human monoclonal antibody of the IgG4 type that targets human programmed cell death protein-1 (PD-1) and reverses the inhibition of the immune response mediated by the PD-1 pathway, thereby activating the body's anti-tumor immune response. The product is a commodity.
Investor Optimism Abounds CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) But Growth Is Lacking
CSPC Innovation Pharmaceutical (300765.SZ) spent a total of 91,129,600 yuan to repurchase 0.23% of its shares.
CSPC Innovation Pharmaceutical (300765.SZ) announced that, as of May 31, 2024, the company repurchased 3,177,200 shares of its own stock through a stock repurchase dedicated securities account by means of centralized competitive bidding trading, accounting for 0.23% of the company's current total share capital. The highest fill price was 34.99 yuan/share, and the lowest fill price was 18.68 yuan/share. The total amount paid was 911,296,433.35 yuan (excluding transaction fees).
The Total Return for CSPC Innovation Pharmaceutical (SZSE:300765) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
New Novus (300765.SZ): A total cost of 39.2313 million yuan to buy back 1.488,200 shares
On May 7, GLONGHUI (300765.SZ) announced that as of April 30, 2024, the company had repurchased 1.488,200 shares of the company's shares through a special stock repurchase securities account, accounting for 0.11% of the company's current total share capital. The highest transaction price was 34.99 yuan/share, the minimum transaction price was 18.68 yuan/share, and the total amount paid was 39.2313 million yuan (excluding transaction fees).
CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
No Data
No Data